EUDA (NASDAQ: EUDA) launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen on Dec 23, 2025, accelerating its regenerative-medicine strategy.
The company is upgrading Shenzhen Inno’s cGMP facility into a production and innovation center integrating GO POSB’s iPSC platform and technologies from two Japanese partners to support iPSC expansion, stem cell preparation and T-cell immunotherapies. EUDA also holds distribution rights for Shenzhen Inno’s T-cell immunotherapies and stated an intention to acquire GO POSB.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.